- Home
- GLAD vs AQST Comparison
GLAD vs AQST Comparison
Compare GLAD & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLAD | AQST |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | United States |
| Employees | 65 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 441.5M | 529.4M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | GLAD | AQST |
|---|---|---|
| Price | $18.67 | $3.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $22.33 | $9.00 |
| AVG Volume (30 Days) | 144.4K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | $15.16 | $10.08 |
| Revenue Next Year | $5.10 | $49.60 |
| P/E Ratio | $11.70 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $16.54 | $2.94 |
| 52 Week High | $27.59 | $7.55 |
Technical Indicators
Market Signals| Indicator | GLAD | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 39.87 | 37.30 |
| Support Level | $18.17 | $3.16 |
| Resistance Level | $18.94 | $4.35 |
| Average True Range (ATR) | 0.42 | 0.20 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 4.97 | 18.55 |
Price Performance
Historical ComparisonAbout GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.